Esplugues De Llobregat

• The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency Ended
  2023-507382-26-00 5 2024-05-24 Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
• Safety and Immunogenicity of V116 in Children and Adolescents With Increased Risk for Pneumococcal Disease Ended
  2023-506236-32-00 5 2024-03-25 Pneumococcal disease
• Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131 Ended
  2023-505844-21-00 3 2024-02-14 juvenile idiopathic arthritis
• A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion … Ended
  2024-512624-11-00 3 2023-12-15 Duchenne muscular dystrophy (DMD)
• Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SAR442501 in pediatric participants with Achondroplasia Ended
  2023-503677-37-00 4 2023-10-24 Osteochondrodysplasia
• An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children a … Ended
  2023-503678-18-00 4 2023-10-10 Autism spectrum disorders
• A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep … Ended
  2022-503067-15-00 5 2023-10-02 Tuberous Sclerosis Complex (TSC) related epilepsy
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended
  2022-501476-25-00 5 2023-09-12 Atopic Dermatitis Eczema
• Long-term extension study of ligelizumab in food allergy Ended
  2022-502366-25-00 5 2023-09-11 Food allergy
• Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression Ended
  2024-513457-70-00 4 2023-09-08 Treatment-Resistant Depression (TRD)
• Basimglurant in children, adolescents, and young adults with TSC Ended
  2024-512611-53-00 4 2023-06-30 Tuberous Sclerosis Complex
• A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly … Ended
  2022-500275-31-00 5 2023-06-20 Haemophilia A
• A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended
  2022-501104-10-00 10 2023-06-06 Netherton syndrome (NS)
• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn … Ended
  2023-508777-91-00 10 2023-05-16 Moderately to Severely Active Crohn's Disease
• Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended
  2022-501586-50-00 5 2023-05-15 Atopic Dermatitis
• A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin for the … Ended
  2024-516385-10-00 4 2023-05-02 Acute Bacterial Skin and Skin Structure Infections
• Cook´s balloon versus dinoprostone for Labor Induction of term pregnancies with fetal GROWth restriction (COLIGROW study) Ended
  2024-513523-16-00 5 2023-03-16 Fetal growth restriction
• A clinical study to evaluate mRNA-3705 in Patients with MMA Ended
  2022-502492-32-00 7 2023-02-03 Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Defici
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Dose … Ended
  2024-513119-29-00 4 2022-12-02 PMM2-CDG
• A Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing's Sarcoma Ended
  2023-506772-28-00 4 2022-10-07 Ewings Sarcoma
• Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa Ended
  2024-513859-33-00 5 2022-08-26 Glycogen storage disease type II
• Tralokinumab monotherapy for children with moderate-to-severe atopic dermatitis. Ended
  2024-512791-36-00 4 2022-08-24 Treatment of moderate-to-severe Atopic dermatitis
• A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose comb … Ended
  2024-518527-29-00 4 2022-05-24 Polycystic ovary syndrome (PCOS)

Showing 265–288 of 323 trials